td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8366 [post_author] => 235 [post_date] => 2019-10-09 12:22:22 [post_date_gmt] => 2019-10-09 02:22:22 [post_content] => About half of school leavers (schoolies) believe emergency contraception is only effective 12 or 24 hours after sexual intercourse, according to a new study urging a re-think of the term “morning after pill”. Led by researchers from Griffith University’s School of Pharmacy and Pharmacology and published in the Journal of Pharmacy Practice and Research, the study analysed 500 responses from teenagers 'on the first day of the Queensland Schoolies Week' at Surfers Paradise in 2017, with the aim of '[exploring] the awareness of ... schoolies regarding the use and availability of emergency contraception'. It found 65% of respondents were unaware that emergency contraception (EC) was available from a community pharmacy without prescription and 25% believed the medication was harmful. Although oral levonorgestrel has been available as a non-prescription EC in Australia since 2004 (with ulipristal made available without prescription in 2017), the researchers said consumer awareness of EC in Australia has been ‘traditionally poor’. While the rates of understanding of EC in respondents paralleled the general population, the researchers, led by pharmacist and lecturer Denise Hope, said schoolies are a more vulnerable cohort.
"Morning after” a misnomerAlthough levonorgestrel is approved for use up to 3 days after unprotected sex, and ulipristal for up to 5 days, just 18.5% of survey respondents said they believed EC to be effective either 72 or 120 hours after sex. University of New England Pharmacy Lecturer Anna Barwick MPS said pharmacists have an important role to play in reducing the misinformation around EC, beginning with the terminology. ‘As pharmacists, we need to change the language and call it an “emergency contraceptive” rather than the morning after pill,’ Ms Barwick told Australian Pharmacist. ‘It’s misleading; calling it the “morning after pill” suggests it can only be used in that timeframe. ‘It’s quite clear from this research that people take it to mean that and believe it is potentially only effective for the morning after, which is incorrect.’
Education and engagementMs Barwick said community pharmacists are well-placed to engage with young women about EC, for example when a customer is picking up her regular oral contraceptive. ‘We need to use our opportunities to speak to younger women, and women of childbearing age more broadly, so they understand what’s available to them,’ she said. ‘You can explain that EC is an option if they have missed one of their regular contraceptive pills or they have been vomiting or experienced something else that might affect the absorption, and therefore the effectiveness, of their regular contraception.’ This could also lead to a broader conversation about the different methods of contraception available to women, Ms Barwick said. ‘I think women, and young women in particular, often feel it’s limited and that there’s only the oral contraceptive, but we have IUDs and other options now, which is fantastic,’ she said. ‘As pharmacists, we’re very well placed to discuss those options and refer women back to their regular GP or healthcare provider who can prescribe these options.’ She said community pharmacists could also play a more active role in educating younger generations. ‘I feel that there’s not enough known [about EC] and it’s not discussed openly,’ Ms Barwick said. ‘Our job is to improve the use of medicines and make sure people are confident about using them in the right way. ‘I’d encourage my colleagues to try and get into schools or go to events where they can have these open conversations.’ [post_title] => Pharmacists can teach 'schoolies' about emergency contraception [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => pharmacists-can-teach-schoolies-about-emergency-contraception [to_ping] => [pinged] => [post_modified] => 2019-10-10 11:00:02 [post_modified_gmt] => 2019-10-10 01:00:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=8366 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Pharmacists can teach ‘schoolies’ about emergency contraception [title] => Pharmacists can teach ‘schoolies’ about emergency contraception [href] => https://www.australianpharmacist.com.au/pharmacists-can-teach-schoolies-about-emergency-contraception/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 8368 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8298 [post_author] => 11 [post_date] => 2019-10-06 00:11:54 [post_date_gmt] => 2019-10-05 14:11:54 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text]The Royal Commission into Aged Care Quality and Safety has heard clear calls for pharmacists, as a priority, to spend more time on the ground in residential aged care. Hearing from dozens of witnesses and receiving hundreds of submissions, the Royal Commission has travelled the length and breadth of the country in recent months. But one clear theme has been the importance of safe and quality use of medicines, said PSA National President Associate Professor Chris Freeman. ‘Given the evidence presented, PSA believes it highly unlikely that the commission will fail to recommend an expanded role for pharmacists in residential aged care facilities (RACFs),’ he said. The commissioners are not required to provide an interim report until 31 October, and their final report is not due until 30 April next year. In the meantime they will be sorting through vast amounts of compelling evidence, including that presented by Dr Janet Sluggett from Monash University’s Centre for Medicine Use and Safety. ‘I emphasised to the commissioners the urgent need for a subsidised model of practice which enables pharmacists to be integrated within RACFs to provide clinical pharmacy services and support quality use of medicines,’ Dr Sluggett recounted. ‘Pharmacists can identify medicines-related problems, help to resolve those problems and prevent future medicine-related problems from occurring. Bringing pharmacists closer to the point of care will increase capacity to identify and resolve the medicine-related problems that we are seeing in RACFs.’
Reducing antipsychotics and benzodiazepinesThe prescribing of antipsychotics and benzodiazepines was high on the Royal Commission’s agenda after a number of alarming media reports on the use of physical and ‘chemical’ restraints. Dr Juanita Breen (previously Westbury) from the Wicking Dementia Research and Education Centre was asked about her findings from the RedUSe study,1 which looked at antipsychotic and benzodiazepine prescribing – just one example of medicine safety problems – in more than 12,000 aged care residents. ‘In some homes you had 45% of residents taking an antipsychotic every single day, but on the other end of the scale you had some with 6% of residents,’ Dr Breen told the commission. ‘Some homes are very quick to rush to the medication for management, whereas other homes are much more prudent.’ Dr Breen added: ‘The RedUSe program provided substantial evidence that a pharmacist-led program, incorporating quality improvement strategies and review, can significantly reduce the rate of psychotropic use and promote their review in aged care.’ The commission also heard from a registered nurse who was asked: ‘Why is chemical restraint used in residential care?’ ‘Because there’s not enough staffing,’ responded the nurse, known as Elizabeth. ‘It’s really confronting and unsavoury to physically restrain people, and ... I can’t think of a time where it actually should be happening at all ... rather than give proper care, you just sedate people so then they’re not annoying you ... It’s not acceptable.’
Inappropriate prescribing and polypharmacyThe use of medicines overall was another key concern reflected in statements from Dr Robert Herkes, the Chief Medical Officer at the Australian Commission on Safety and Quality in Health Care. Dr Herkes spoke about the need to ensure that residents at RACFs receive the best outcomes from multiple medicines. ‘One of the things we were keen to think about adding to the standards is around medication review,’ he said. ‘It’s around the appropriate use of medicines, and making sure high-risk medicines, like antipsychotics, are treated with respect rather than handed out without due diligence.’ The Age Discrimination Commissioner, Dr Kay Patterson, also raised concerns about medicines in aged care noting the lack of medicines reviews, particularly in the context of residents returning from hospital. ‘I have a large number of general practitioner friends ... and pharmacy friends .... who are appalled that there isn’t sufficient review of medication,’ Dr Patterson said. PSA’s recent report – Medicine Safety: Take Care – showed that 98% of residents in an RACF have at least one medicine-related problem and over half are exposed to at least one potentially inappropriate medicine, said A/Prof Freeman. ‘Pharmacists, with their unique expertise in medicines and medicine management, are ideally placed to identify and help resolve these issues,’ he said. ‘It is really quite alarming that the safe and quality use of medicines, especially the inappropriate use of antipsychotic medicine, appears to have not improved within RACFs over the past five years.’ Medicines administration and management has been the number one issue raised with the Aged Care Complaints Commissioner in recent years.2
Embedding pharmacists in RACFsIn order to address these issues the Australian Government’s Chief Medical Officer, Professor Brendan Murphy, told the Royal Commission that embedding pharmacists in RACFs was a priority. ‘The [Aged Care Clinical Advisory] Committee’s view was that the highest priority was probably the embedded pharmacist,’ he told the court. ‘There is ... `available pharmacy workforce now and the trial results showed the benefit and there’s a benefit well beyond psychotropic medication.’ Professor Murphy added that the option of embedding part-time pharmacists in aged care facilities was also being considered ‘to promote the clinical governance around medication more broadly, not just psychotropic medication’. Embedding pharmacists in RACFs could also help to deliver more needed collaborative care. GP Professor Dimity Pond told the Royal Commission that in her time in RACFs, case conferences involving health professionals such as geriatricians, pharmacists and other health professionals occurred ‘very rarely’. This was attributed to the lack of remuneration for non-GP health professionals to attend. ‘They don’t pay the facility ... the geriatrician, the other allied health or the pharmacist to attend,’ said Professor Pond, the Head of the Discipline of General Practice at the University of Newcastle, who has a special interest in dementia. ‘They will come in their own time and unremunerated ... this needs to be sorted.’ Dr Breen also stressed the importance of pharmacists working more effectively with staff. ‘Pharmacists ... who worked in the sector often said that they encountered real resistance to actually reduce the overall use, because a lot of the staff were quite concerned that behaviours would return or be escalated if the use was reduced,’ she said. Pharmacists were ‘ideally placed to provide education and training in this area’, Dr Sluggett told the commission. ‘I was asked to present results from research at the Registry of Older South Australians, which showed a sharp increase in antipsychotic use in the year before individuals entered an RACF. In the three months after entering an RACF, one third of all residents living with dementia receive an antipsychotic,’ she said. ‘This evidence, drawn from over 97,000 Australians residents, suggests increased education and support around nonpharmacological strategies to manage the behavioural and psychological symptoms of dementia will be key to minimise antipsychotic use in RACFs,’ Dr Sluggett said.
Terry Reeves: Royal Commission case study on antipsychotic useA photo shows Terry Reeves bright and alert – looking young for his 72 years – on his first day of respite care at a western Sydney nursing home. Seven weeks later he is pictured slumped in his chair, having lost weight and quite visibly aged. ‘When Terry came home, he was totally incontinent. He laid on the floor and he couldn’t move or eat anything independently,’ his wife, Lillian Reeves, said in a statement to the Royal Commission into Aged Care Quality and Safety. ‘He could barely walk. He could only shuffle with assistance.’ Reeves’ family has claimed that during his 61-day stay at Garden View Nursing Home, Reeves was given risperidone without their knowledge or consent. Records examined by the Royal Commission showed that Dr Kenneth Wong prescribed 0.5 mg of risperidone at night. ‘The nursing staff informed me that the low dose risperidone [0.25 mg tds on an ‘as needed’ basis] was not effectively managing Mr Reeves’ distress, his wandering or his behaviour and the wandering was creating a risk of falling,’ Dr Wong told the commission. ‘I advised the nursing staff that, considering Mr Reeves was at risk of falling if he continued to wander around the nursing home, they could use a belt restraint if they were unable to moderate that behaviour by other means.’ Reeves’ family told the commission they were repeatedly told that he was restrained because he had been aggressive. Reeves’ daughter, Natalie Smith, told the Royal Commission: ‘Almost every time I visited Dad (more than 20 visits and no more than three days apart), I would arrive to find he was restrained in a chair in the east wing, often without shoes or a jumper and on some occasions having wet through his pants,’ she said. Following an ABC report that Reeves was restrained for a total of 14 hours on one day,⁷ the then-Aged Care Minister Ken Wyatt introduced the Quality of Care Amendment (Minimising the Use of Restraints) Principles 2019.8
AGED STATISTICS· 98% of RACF residents have at least one medication-related problem3 · OVER HALF of RACF residents are exposed to at least one potentially inappropriate medicine3 · 36% of older Australians are affected by continuous polypharmacy (935,240 people)4 · 248,163 medicine-related hospitalisations of elderly Australians per annum3 · 52% increase in elderly people affected by polypharmacy between 2006–20174 2017: · 3.8 million Australians aged 65+ · 232,000 people aged 65+ in permanent residential aged care5 2040: · 458,000 aged care beds needed6 2057: · 8.8 million Australians aged 65+5
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8237 [post_author] => 250 [post_date] => 2019-10-02 12:03:57 [post_date_gmt] => 2019-10-02 02:03:57 [post_content] => Medicine access, technological disruption to traditional care models, ethical dilemmas and gender equity dominated the program for the 79th International Pharmacy Federation (FIP) Congress. The congress wrapped up in Abu Dhabi, United Arab Emirates, on Thursday attended by 2,652 delegates from 115 countries. Australian pharmacists played key roles chairing sessions and workshops and presenting new research. Some of the highlights of the congress follow.
Ethical dilemmas: conscientious objection and moral stressAssociate Professor Betty Chaar MPS, lecturer in professionalism in pharmacy at the University of Sydney chaired a session which explored the tension between the rights of pharmacists as individuals to practice in a way which does not conflict with moral beliefs and the rights of consumers not to have the beliefs of the practitioner imposed on them. [caption id="attachment_8256" align="alignright" width="200"] Sami Isaac MPS[/caption] The session explored the various rights and responsibilities of pharmacists around the world in areas such as reproductive health, voluntary assisted dying and in relation to people who use illicit drugs. A discussion session was expertly facilitated by Sami Isaac MPS, pharmacist and PhD candidate at the University of Sydney, through cases examining pharmacists’ rights to conscientious objection in relation to reproductive health. The diversity of experiences from colleagues around the globe empowered delegates to be more self-aware through a rich, nuanced and reflective discussion.
Hot topics: Gender equity, internet pharmacy and antimicrobial stewardshipTana Wuliji (World Health Organisation, New Zealand), Nadia Bukhari (FIP Global Lead, Gender Equity, Pakistan) and Dr Catherine Duggan (FIP CEO, United Kingdom) challenged pharmacy leaders to champion gender equity in health care, presenting compelling data which demonstrate the whole health care workforce benefits when gender equity is higher. FIP’s work in this area can be followed with the social media hashtag #equityrx. [caption id="attachment_8248" align="alignnone" width="1280"] Ardalan Mirzaei MPS discussing internet pharmacy models[/caption] Ardalan Mirzaei, MPS, another pharmacist PhD candidate at the University of Sydney, joined speakers from Malaysia, Portugal and Nigeria to explore different internet pharmacy models globally, and how contemporary pharmacists need to be alert to and support consumers accessing medicines via ‘rouge websites’ and the ‘dark web’.
Non-communicable diseases: FIP position statementFIP emphaised the value of pharmacists in the global fight against non-communicable diseases (NCDs), in a statement of policy published during the congress. NCDs such as diabetes and cardiovascular disease pose one of the greatest health risks for humanity. This demands new answers and creative solutions from health systems and healthcare professionals. ‘This policy statement renews the commitment of the pharmacy profession to the prevention of NCDs, and the optimal detection and care of patients living with NCDs,’ said Eeva Teräsalmi, FIP vice president and chair of its NCD Policy Committee. The policy was released following endorsement by the FIP Council, of which PSA is a voting member organisation. It aligns strongly with actions described in PSA’s Pharmacists in 2023 report to use pharmacists’ expertise to optimise outcomes through collaborative care models and enhance pharmacists’ role in public health initiatives, such as case detection and risk assessment.
An Australian to lead young pharmacists[caption id="attachment_8249" align="alignright" width="250"] Dr Renly Lim MPS (left) with other members of the YPG Steering Committee[/caption] Dr Renly Lim MPS, a research fellow at the University of South Australia, is the new president-elect of the FIP Young Pharmacists Group. ‘I’m humbled and honoured to be elected,’ Dr Lim said. ‘I’ve got so much to learn and I’m excited to continue working with the steering committee and to be leading YPGs in 2021.’ Dr Lim was also awarded first place in the Social and Administrative Pharmacy Section poster competition for her research on opioid use in Australian adults following elective surgery.
World Pharmacist Day with (world) pharmacistsIn a rare alignment of dates, this year’s congress aligned with World Pharmacist Day, celebrating the roles of pharmacists in supporting safe and effective medicine use for all. [caption id="attachment_8250" align="alignnone" width="1449"] Celebrating World Pharmacists Day in Abu Dhabi. From left: Hannah Knowles MPS (Queensland), PSA Senior Pharmacist, Strategic Policy, Peter Guthrey MPS (Victoria), Vivien Tong (NSW) and Nomaphelo Krakri (South Africa)[/caption] To kick off the day, delegates celebrated by sharing in WPD cupcakes while reflecting on the work of pharmacists globally to safeguard the public from medicine-related harm.
Future congressNext year’s FIP Congress will be held in Seville, Spain in mid-September. Abstracts for FIP Congress posters and short oral presentations usually open late in the year and close in early April. In August 2021, Brisbane, Australia will be hosting pharmacists and pharmaceutical scientists from around the globe. The conference committee held a brainstorming session for session proposals in Abu Dhabi, with collaborative sessions exploring the conference theme strongly encouraged. Following a competitive selection process, Cape Town, South Africa was announced as the host city for the FIP Congress in 2022. [post_title] => Hot topics at the 2019 FIP Congress [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => hot-topics-at-the-2019-fip-congress [to_ping] => [pinged] => [post_modified] => 2019-10-03 09:49:56 [post_modified_gmt] => 2019-10-02 23:49:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=8237 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Hot topics at the 2019 FIP Congress [title] => Hot topics at the 2019 FIP Congress [href] => https://www.australianpharmacist.com.au/hot-topics-at-the-2019-fip-congress/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 8238 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8200 [post_author] => 235 [post_date] => 2019-10-02 10:35:16 [post_date_gmt] => 2019-10-02 00:35:16 [post_content] => Pharmacists across Australia and the globe came together on 25 September to celebrate the 10th annual World Pharmacists Day. With the theme of ‘safe and effective medicines for all’, World Pharmacists Day 2019 highlighted the crucial role pharmacists play in safeguarding patient safety by improving medicines use and reducing medication errors. The PSA chose the day to launch its refreshed My Health Record (MHR) Guidelines for Pharmacists and celebrated with events across the country.
Australian Capital TerritoryAt a breakfast in Canberra, Director of the Australian Digital Health Agency’s Medicines Safety Program Andrew Matthews spoke about the advantages of pharmacists having access to patient records. ‘He was enthusiastic about the benefits GPs were already seeing from immediate access to patients’ hospital discharge records,’ ACT Branch committee member Kara Sellwood said. ‘For me, the highlight was his explanation of paperless scripts and the challenges and opportunities facing community pharmacies as they redesign workflow practices.’
VictoriaPSA’s Victorian branch marked the occasion with a discussion on the future of digital innovations in the profession, with pharmacist Robert Sztar sharing his passion for using technology to deliver better patient-focused care. [caption id="attachment_8224" align="alignright" width="250"] PSA Queensland President Chris Campbell[/caption]
Cooroy, Townsville, Sunshine CoastIn the Sunshine State, PSA Queensland Vice President Jacquie Meyer hosted a morning tea at her pharmacy in Cooroy, while 35 pharmacists attended an event at the Fox Hotel in South Brisbane. Queensland Early Career Pharmacists (ECP) Working Group members James Buckley and Andrew Calabro also participated, with Mr Buckley holding an event on the Sunshine Coast and Mr Calabro spending the day visiting pharmacies in Townsville.
TasmaniaMeanwhile, in Tasmania, PSA branch members provided a sweet note to the day, distributing 70 cakes to pharmacies across the island. Emily Thorp, a PSA Professional Practice Pharmacist, said the team spoke to 25% of Tasmanian PSA members and visited pharmacies involving 45% of members. [caption id="attachment_8273" align="alignnone" width="560"] Pharmacists in Glenorchy, Tasmania[/caption] ‘We also targeted members in a range of practice settings, including: general practice, compounding, Primary Health Tasmania, the University of Tasmania, and pharmacists at the state’s major hospitals,’ Ms Thorp said.
Northern TerritoryIn the Northern Territory, the Federal Member for Solomon, Luke Gosling, spoke at an event in Darwin, praising the work of pharmacists. ‘Anything we can do that is preventative and helps people manage their medicines is going to mean better health for everyone, and the people who have that expert knowledge are pharmacists,’ Gosling said.
South Australia[caption id="attachment_8245" align="alignright" width="250"] SA pharmacists celebrate with a selfie[/caption] Chair of the South Australia (SA) ECP Working Group Renae Lloyd hosted a networking evening for Adelaide pharmacists. PSA SA Branch Manager Helen Stone said it was a great opportunity to meet new contacts and catch up with old friends. ‘There were about 50 attendees, which included students, interns and pharmacists,’ Ms Stone said. ‘We saw members and non-members we don’t normally see. It was nice to welcome new faces and there were lots of photos taken with our Instagram selfie prop.’
New South Wales
Orange, SydneyAt a breakfast in Orange, New South Wales (NSW), attendees heard about the value pharmacists bring to health from a range of speakers, including Charles Sturt University Associate Professor Maree Simpson, National Australian Pharmacy Students' Association President Erin Cooper, and Assistant Minister to the Deputy Prime Minister Andrew Gee. [caption id="attachment_8222" align="alignright" width="1280"] NSW pharmacists enjoying the Sydney celebrations[/caption] Those in Sydney had the opportunity to attend an evening event with the Federal Member for Dobell Emma McBride, the University of Sydney’s Dean of Pharmacy, Professor Andrew McLachlan, NSW PSA President Professor Peter Carroll, and Amy Murray, Director of Pharmacy at Blacktown and Mount Druitt Hospitals. NSW ECP Working Group members also presented a range of inspiring TED Talks, including Rainy Yuchen Johnson, who highlighted the possibilities of MHR for pharmacists and the opportunity it presents to provide better patient outcomes.
Western AustraliaOn the other side of the country, PSA’s Western Australia (WA) branch hosted an evening for young and experienced pharmacists, with branch president and PSA ECP of the Year, Dr Fei Sim, sharing some thoughts on how to ensure medicine safety for all. WA ECP Working Group member Jo Armstrong had this World Pharmacists Day message to share:
A global celebrationWorld Pharmacists Day began in 2009 at the Federation of International Pharmacists (FIP) World Congress in Istanbul, as a way to promote the work of pharmacists. Hundreds of professionals celebrated together at this year’s congress in Abu Dhabi, while other events highlighted the different issues pharmacists face around the globe. The Pharmaceutical Society of Kenya used the day to launch new guidelines on distribution practices and the disposal of pharmaceutical waste, while the Royal Pharmaceutical Society of Great Britain and Pharmaceutical Society of Nigeria announced a new strategic partnership to improve patient care. In Canada, the Canadian Pharmacists Association shared pharmacists’ stories on social media as part of its #rethinkpharmacists campaign. This aims to remind the community that pharmacists are ‘convenient, accessible and close to home’. [post_title] => Role of pharmacists recognised around the world [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => role-of-pharmacists-recognised-around-the-world [to_ping] => [pinged] => [post_modified] => 2019-10-03 09:54:34 [post_modified_gmt] => 2019-10-02 23:54:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=8200 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Role of pharmacists recognised around the world [title] => Role of pharmacists recognised around the world [href] => https://www.australianpharmacist.com.au/role-of-pharmacists-recognised-around-the-world/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 8211 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8193 [post_author] => 243 [post_date] => 2019-10-01 10:33:02 [post_date_gmt] => 2019-10-01 00:33:02 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text]How pharmacists can respond to Aboriginal and Torres Strait Islander community needs in an integrated, collaborative way that uses their full set of skills. There is no doubt that preventable medicine-related problems persist in Australia today. The prevalence of this issue has piqued interest at all levels of the pharmacy sector. This includes the Federal Minister for Health, the Hon Greg Hunt MP, who has formally made a commitment to make the quality and safe use of medicines a National Health Priority Area. Something new and different needs to be done across health settings to enhance the impact that pharmacists can have on this issue. To compound the medicine-related challenges, Australia has an ageing and increasing population, where rates of chronic disease are likely to continue to rise. Accordingly, there seems much discussion in the pharmacy community related to the future of pharmacy, and how future practice and programs may address these medication-related problems and the associated public health challenges. Over the last 12 months, there have been several noteworthy developments. Two major Australian pharmacy bodies – PSA and the Pharmacy Guild of Australia – have released their visions for pharmacy into the future (PSA’s Pharmacists in 2023 and the Pharmacy Guild’s Community Pharmacy 2025). Australia’s National Digital Health Strategy proposes that ‘better availability and access to prescriptions and medicines information’ is one of seven strategic priority outcomes to be achieved by 2022. In addition, the 7th Community Pharmacy Agreement (7CPA) negotiations have begun, drawing our attention to what this future agreement may hold for the pharmacy profession and industry generally. There is also a possibility that the National Medicines Policy will be reviewed in the coming year, after its launch 20 years ago in 1999. Aboriginal and Torres Strait Islander people are referenced in each of the five policy items named above. There is clearly an intent within the Australian Government and pharmacy and health sectors to consider the medicine-related priorities for Aboriginal and Torres Strait Islander people and work with them to address these.
So, what is the vision?Both PSA and the Guild’s future documents frequently reference integration and collaboration, and how pharmacists may have a bigger role within healthcare teams. Integrated team-based health care is an emerging theme globally and the Health Care Home model is one example of trialling such an approach in Australia.
How might this integration be achieved?For nearly half a century, Aboriginal Community Controlled Health Organisations (ACCHOs) have been delivering comprehensive, collaborative and integrated services related to health and wellbeing that align with local Aboriginal and Torres Strait Islander communities’ needs. Around 145 ACCHOs now operate in all states and territories, governed by elected local community members, and are therefore connected and accountable for the services that are being delivered. Their sizes and models of care vary greatly between services, but ACCHOs may offer some useful insights and lessons for the health sector generally. In relation to integration and collaboration, ACCHOs have been innovative and dynamic, and have led this style of practice in the Australian health sector for some years. As such, several ACCHOs around Australia have prioritised how they deal with medicines by integrating pharmacists’ clinical and consulting services into their models of care. Such leadership dates back around two decades. Interestingly, evidence from a recent large systematic review of pharmacists working within a primary care practice setting, demonstrates that the degree of integration was strongly and positively correlated with the patient-centred clinical impact of the pharmacist in the general practice or health service.1 ACCHOs are commonly made up of highly integrated, multidisciplinary teams. These teams may include a very broad range of staff, such as Aboriginal health practitioners, nurses, GPs, diabetes educators, specialists, youth workers, psychologists, dentists, pharmacists and more. Their activities are often managed and coordinated by a local executive team and ultimately overseen by the community boards. In such a structure, substantive integration and collaboration can be well supported. ACCHOs often have organisational structures that support clinical and medicines governance and continuous quality improvement. The organisation may have the will and capacity to develop comprehensive medicines policy and processes for all staff, external organisations and clients – for example, a standard medicines formulary for use across ACCHO clinics.
Full scope of skillsEnsuring pharmacists are utilising their full scope of skills and knowledge is also a key theme within Australian pharmacy organisations’ current policy. Pharmacists have a range of skills that sit well within those of an overall primary healthcare team. This is demonstrated in the breadth of work they currently perform in the ACCHOs across Australia. Services delivered in ACCHOs are diverse, but may include counselling, providing GP registrar education, conducting prescribing audits, developing imprest policy, managing vaccine procurement and storage, improving discharge communication with local hospitals and more. The pharmacists currently working within ACCHOs can discuss and review how their scope and individual skills can be best used or developed to deliver the outcomes most needed by the ACCHO and community. As the burden of chronic diseases continues to increase, managing these conditions or multiple diseases can be complex and involve numerous healthcare staff and organisations. Medicines will continue to be a critical component chronic disease management. Pharmacists can work within the ACCHO team, which often employs chronic disease care coordination staff, to ensure continuity of best-practice care and medicines use for chronic disease clients. The current plans and commentary from pharmacy and health leaders are positive and healthily aspirational, but there must be ongoing and adequate support from governments and pharmacy bodies as plans become actions. Plans and programs must materially capture the support needed for pharmacists to integrate into primary care teams, including ACCHOs.
Recent developmentsNational leadership and action related to Aboriginal and Torres Strait Islander medicines use is exemplified in several recent developments. For example, funding of two 6CPA Pharmacy Trial Programs, which investigate novel integrated and collaborative approaches involving Aboriginal and Torres Strait Islander patients and ACCHOs.2 Also, recommendations made by the Medicare Benefits Schedule Allied Health Reference Group to allow pharmacists to provide medication management services to patients with complex care requirements as part of Team Care Arrangements. Integration and collaboration must be done in a way that is responsive to communities’ and patients’ needs. For example, a general practice or ACCHO may be supported, scope and identify their own medicines needs and then recruit a suitable pharmacy or pharmacist to work within their clinic and team environment to address these issues. In scoping and understanding communities’ medicines needs (e.g. diabetes medicines education, GP prescribing training, atrial fibrillation prescribing audit), the health service must consider how existing medicines players – community pharmacies, hospitals and specialists – will integrate into the work_ ow and team-based approach. How will medicines dispensing and counselling integrate with patient education sessions? How will community pharmacy DAA supply and systems integrate with a local Home Medicines Review program? Pharmacists’ accountability to patients and communities can be supported by ensuring community and Aboriginal governance is enshrined within new and existing pharmacy programs.
How to go localWhile systems change, such as pharmacy policy (e.g. the future documents and new MBS item), emerging digital systems and health programs offer many solutions. Individual pharmacists also need to have the initiative and confidence to address integration and collaboration challenges at a local level. There are excellent resources related to Aboriginal and Torres Strait Islander health and medicines use on the PSA website and members’ portal (www.psa.org.au), the NACCHO website and the Pharmacy Guild of Australia website (www.guild.org.au). Regardless of what the future may hold, I encourage all pharmacists to start (or continue) engaging with your local Aboriginal and Torres Strait Islander organisations and clinics today – you may find there are many ways that you can collaborate and integrate your services to improve the health of your community. References
[/vc_column_text][/vc_column][vc_column width="1/3"][/vc_column][/vc_row] [post_title] => Medicines as a team sport [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => medicines-as-a-team-sport [to_ping] => [pinged] => [post_modified] => 2019-10-02 10:19:53 [post_modified_gmt] => 2019-10-02 00:19:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=8193 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Medicines as a team sport [title] => Medicines as a team sport [href] => https://www.australianpharmacist.com.au/medicines-as-a-team-sport/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 8198 )
- Hazen AC, De Bont AA, Boelman L, et al. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: a systematic review. Res Social Adm Pharm 2018;14(3):228–240. At: https://www.ncbi.nlm.nih.gov/pubmed/28506574
- For more information on both trials visit: health.gov.au/internet/main/publishing.nsf/Content/pharmacy-trialprogramme
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8361 [post_author] => 255 [post_date] => 2019-10-09 11:47:01 [post_date_gmt] => 2019-10-09 01:47:01 [post_content] => Adapted by Ann Winkle MPS. Charcot–Marie–Tooth disease (CMT) is the most commonly inherited neuromuscular disorder, affecting almost 10,000 Australians.1,2,3 About one in three CMT patients require a mobility aid.2 Some are susceptible to medicine-induced neurotoxicity.
Could this be any of your patients?CMT affects both sensory and motor peripheral nerves, gradually resulting in reduced sensation and muscle weakening. As CMT tends to affect distal points first, symptoms start in the feet and progress proximally.1 Severity, progression and age of onset vary widely. People with more common forms of CMT typically live a normal lifespan.2 Those with the rare childhood form of CMT (diagnosed before 10 years of age) usually have profound limitation in activities. CMT results from mutations in genes involved in peripheral nerve function. Although not fully understood, nerve conduction velocity is reduced. Electrical impulses do not reach target muscles, causing weakness, atrophy and sensory loss.4,5 Familial inheritance can be autosomal dominant, autosomal recessive or X-linked recessive, depending on the specific mutation involved.6 Cases of sporadic mutations have also been documented.1 There are many genetic variations with CMT1 (demyelinating form) being the most common form, followed by CMT2 and CMTX (both axon abnormalities). Many patients don’t know their CMT subtype.2,7 Symptoms commonly appear in adolescence or early adulthood but can be earlier or later. An Australian survey found that the median age of diagnosis was 33.5 years, with most diagnoses in the age cohort of 45–49.2 Common signs and symptoms:1,2
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8357 [post_author] => 23 [post_date] => 2019-10-09 11:11:12 [post_date_gmt] => 2019-10-09 01:11:12 [post_content] => In a landscape of increasing opportunities for pharmacists, last week PSA launched its foundation stage training program for those wanting to work as a general practice pharmacist.1 Are you looking for the next step in your career? Discover the rewards of working at the coalface of primary care – talking to patients about managing their medicines, identifying medicine issues, influencing prescribing choices, collaborating with GPs and the primary care team, and ensuring quality use of medicines is embedded in patient care. As a relatively new phenomenon in Australia, working as a general practice pharmacist may be uncharted territory for both the pharmacist and the general practice. The role needs to be developed in collaboration with new colleagues. Consider how to obtain patient consultations, what practice-level activities (e.g. clinical audits) to undertake, and what training/education you could provide to patients and fellow health professionals. There may be barriers along the way, but it’s important to be able to take constructive criticism. According to Greer Meredith, a PSA Project Officer working with Primary Health Networks (PHNs) in Melbourne, this proactive approach requires resilience and robustness. One person with both is Mina Naguib MPS, a general practice pharmacist working at Glenroy and Calder Medical Centres in the north-west suburbs of Melbourne. His foray into the field began with a PSA-managed pilot program, when he realised this was a career he wanted to pursue. ‘Working in general practice gives me the opportunity to directly collaborate as a member of the multidisciplinary health care team and gain professional satisfaction through using my knowledge and training to improve patients' health outcomes,’ Mr Naguib said. The work can be rewarding, with real differences in patient outcomes. He recalls an elderly patient discharged from hospital on a 14-day course of frusemide and a potassium supplement. Although 14 days of frusemide was supplied, the potassium pack contained 200 tablets. The patient continued taking potassium alone until his post-discharge consultation with Mr Naguib in the third week, who immediately raised the issue with the patient's GP. A biochemistry test that day identified elevated potassium levels. Potassium was ceased and harm was prevented well before the next GP consultation.
PSA and the general practice pharmacistIn its Pharmacists in 20232 report PSA recommends embedding pharmacists in general practice and recognises the need to prepare pharmacists for this new frontier. Its foundation course and practice support tools are available now. For information on the role of the general practice pharmacist, refer to PSA’s Pharmacists in 2023: Roles and Remuneration report.3 As described in the report, it is recommended that pharmacists have these prerequisites:
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 8254 [post_author] => 235 [post_date] => 2019-10-02 14:34:49 [post_date_gmt] => 2019-10-02 04:34:49 [post_content] => Recalls of more ranitidine products are expected to continue this week after preliminary tests found low levels of nitrosamines in the medicines. A spokesperson from the Therapeutic Goods Administration (TGA) told Australian Pharmacist today that initial testing of ranitidine medicines showed 40 out of 44 products tested positive for the contaminant N‑nitrosodimethylamine (NDMA), a nitrosamine. Nitrosamines are commonly found in low levels in a variety of foods, including smoked and cured meats, as well as some drinking water. According to the TGA, long-term exposure, over years, can increase an individual’s risk of developing cancer. The news comes after authorities in Canada and Europe ordered recalls of ranitidine medicines ‘Eleven sponsors currently supply ranitidine products in the Australian market and most, but not all, are affected by the current contamination issue,’ the TGA spokesperson said. ‘As ranitidine is supplied as both prescription-only and over-the-counter medicines, exact numbers of Australians using these products are not readily available.’ Sandoz Australia began a retail-level recall of ranitidine products on 17 September, with Apotex and Aspen Australia, which produces Zantac, following this week. All the companies have advised customers to quarantine any affected stock. Now finalising its testing process, the TGA will discuss appropriate actions with each sponsor on a case-by-case basis. Guidance provided to health professionals in an alert published on 17 September remains relevant. The TGA said pharmacists providing advice to patients accessing ranitidine over the counter should discuss treatment options and review whether ongoing pharmacotherapy is appropriate. [post_title] => More Australian ranitidine recalls expected [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => more-australian-ranitidine-recalls-expected [to_ping] => [pinged] => [post_modified] => 2019-10-03 09:46:07 [post_modified_gmt] => 2019-10-02 23:46:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=8254 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => More Australian ranitidine recalls expected [title] => More Australian ranitidine recalls expected [href] => https://www.australianpharmacist.com.au/more-australian-ranitidine-recalls-expected/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 8258 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7959 [post_author] => 27 [post_date] => 2019-09-27 09:30:07 [post_date_gmt] => 2019-09-26 23:30:07 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text]The popularisation of meprobamate from the 1950s onwards ushered in the dawn of the psychopharmacological era where patients began to look to doctors to ease their daily struggles. Meprobamate, marketed in the USA as Miltown, was the first anxiolytic to be sold on a mass scale following its synthesis in 1950 by Frank Berger and Bernard John Ludwig at Carter Products. Meprobamate’s method of action is unknown, but it is believed to act on multiple sites in the brain such as the thalamus and limbic system. Meprobamate binds to GABA-A receptors interrupting neuronal communication in the reticular formation and spinal cord, resulting in sedation and an altered perception of pain. Subsequently, people using meprobamate have feelings of anxiety and stress relieved, to a small extent, with its duration short-lived at 4 to 6 hours.
Crazy timesLaunched in 1955 and sold as Miltown (after the New Jersey borough, Milltown), the drug was a blockbuster success, with one in 20 Americans taking the drug by 1956 and more than 1 billion tablets prescribed by 1957 – ‘one prescription every second throughout the year’, according to one magazine. It was known as the ‘miracle cure for anxiety’ and became America’s first psychopharmacological ‘wonder drug’ that operated on a neurochemical level, it was argued, to replace a Freudian psychoanalytic approach. The popular press added to the excitement of a ‘new era in mental health’, trumpeted by Newsweek and other magazines. During the craze, pharmacies put signs in their windows saying, ‘No more Miltown’ or ‘More Miltown tomorrow’. Promotion of the drug was extensive with comedian Milton Berle nicknaming himself ‘Uncle Miltown’ on his long-running TV show. As well, users such as Elvis Presley joked about it and the Rolling Stones mentioned it in their 1966 hit song ‘Mother’s Little Helper’. It is even theorised that the cerebral edema which led to the death of martial artist Bruce Lee may have been exacerbated by him taking a mixture of meprobamate and aspirin, which was sold as Equagesic. Scholars have examined how a post-World War II America and fundamental shifts in society helped shape psychopharmacology’s mass appeal. However, by 1965 the dangers of meprobamate addiction and overuse had become apparent and it was reclassified from a tranquilizer to a sedative. In 1967 it was placed under abuse control regulations requiring detailed retention of information on its production and distribution. In 1970, the drug was relisted as a controlled substance after further research revealed it caused psychological dependence. In Canada and the European Union, it has been suspended from sale and is now mostly replaced by benzodiazepines for the treatment of anxiety. Although meprobamate is on Australia’s Standard for the Uniform Scheduling of Medicines and Poisons as a Schedule 4, it is no longer available here. References
[/vc_column_text][/vc_column][vc_column width="1/3"][/vc_column][/vc_row] [post_title] => Running for the shelter of a ‘mother’s little helper’ [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => running-for-the-shelter-of-a-mothers-little-helper [to_ping] => [pinged] => [post_modified] => 2019-09-19 12:02:44 [post_modified_gmt] => 2019-09-19 02:02:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=7959 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Running for the shelter of a ‘mother’s little helper’ [title] => Running for the shelter of a ‘mother’s little helper’ [href] => https://www.australianpharmacist.com.au/running-for-the-shelter-of-a-mothers-little-helper/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( [td_post_template] => single_template_4 ) [is_review:protected] => [post_thumb_id:protected] => 7960 )
- Tone A. The Age of Anxiety: A History of America's Turbulent Affair with Tranquilizers. Basic Books. New York. 2009. At: https://academic.oup.com/ahr/article-abstract/115/3/868/42710
- Drug Bank. At: https://www.drugbank.ca/drugs/DB00371
- Metzl J. “Mother’s Little Helper” The Crisis of Psychoanalysis and the Miltown Resolution. Gender and History. Vol 15. No 2. 2003. P 240-267. At: https://www.med.umich.edu/psych/FACULTY/metzl/07_Metzl.pdf
- Anon, Unsettling facts about the tranquilizers’. Consumer Reports. 1958, p4.
- Caldwell L. The Truth Behind the Life and Death of Bruce Lee. The Los Angeles Times. 1998. At: https://www.latimes.com/archives/la-xpm-1998-aug-17-ca-13848-story.html
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7989 [post_author] => 23 [post_date] => 2019-09-23 10:30:24 [post_date_gmt] => 2019-09-23 00:30:24 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text]Pharmacists play a referring role in supporting patients with dry eye. Dry eye is a common problem, increasing in older age. Most cases are mild, and treatable with topical lubricants and minimising precipitants. However, without clinical investigation it may be difficult to identify the cause of an individual’s dry eye and to treat optimally, or to know whether there is another underlying condition. When a patient seeks advice, the pharmacist needs to know when to treat and when to refer.
What causes dry eye?Dry eye disease, or keratoconjunctivitis sicca, occurs when the quantity and/or quality of tears fail to maintain adequate lubrication on the surface of the eyes. The cause is multifactorial, with an inflammatory component that can worsen the impact on the eye surface.1 The two main types of dry eye disease are aqueous deficiency and evaporative dry eye. Aqueous deficiency occurs with reduced aqueous production from the lacrimal glands. It accounts for 10% of the disease. Sjögren’s syndrome dry eye fits into this category.1 Evaporative dry eye is due to a deficient tear film lipid layer, increasing tear evaporation. It is caused by meibomian gland dysfunction, responsible for over 85% of dry eye disease. Rosacea (an inflammatory skin disease), blepharitis (an inflammatory eyelid disease), staphylococcus infection and seborrheic dermatitis can all disrupt the function of meibomian glands, leading to evaporative dry eye. A complicating factor of tear deficiency may be reduced resistance to infection, a cause and effect of blepharitis.1 Other conditions associated with dry eye are autoimmune disorders (e.g. Sjögren’s syndrome, lupus, scleroderma, rheumatoid arthritis), thyroid disorders, hepatitis C, vitamin A deficiency, facial nerve palsy, proptosis (abnormal protrusion of an eye), radiation therapy and chemical injuries.2,3
What are risk factors for dry eye?Women are more likely to suffer from dry eye due to hormonal changes throughout life, and a greater likelihood of autoimmune disorders. It is more prevalent with advancing age because of less tear secretion. Medicines with anticholinergic effect (e.g. antihistamines, antihypertensives and antidepressants), are associated with dry eye.1-3 Decreased blinking (e.g. too much screen time, Parkinson’s disease), low humidity (e.g. air conditioning), and windy, smoky or dry environments can exacerbate dry eye.1 The condition is also worsened by contact lenses and refractive laser surgery.1,2
How is dry eye assessed?The clinical presentation of dry eye varies considerably. Patients often describe non-specific symptoms such as visual disturbance, grittiness, burning or photophobia. Paradoxically patients can get excessive wateriness, as discomfort triggers reflex tearing. These symptoms may be present in other eye conditions such as ocular allergy, corneal erosion or a foreign body. Therefore, clinical assessment is required to diagnose dry eye disease.1 Jason Holland, National Director of Optometry for the OPTICAL Superstore, advises that an accurate diagnosis by an optometrist would result in the right advice, and a return to the pharmacy for appropriate treatment. See Box 1 for red flags needing prompt referral.4
BOX 1. NICE guidelines for referral to an optometrist or ophthalmologist
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7962 [post_author] => 42 [post_date] => 2019-09-24 09:30:23 [post_date_gmt] => 2019-09-23 23:30:23 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text]I want to implement SafeScript in my pharmacy. What do I do, and how long does the process take? SafeScript is an initiative by the Victorian Government which has established a clinical decision-making tool in the form of a real-time record of all prescriptions for specific medicines. SafeScript draws data from Prescription Exchanges Serivces (PES) when prescriptions for monitored medicines are issued or dispensed. Monitored medicines include all Controlled Drugs, all benzodiazepines, zopiclone, zolpidem, quetiapine and products containing codeine. The service is available to all pharmacists in Victoria, and will be compulsory from April 2020. While not yet compulsory, pharmacists should be using this system now. One of the effects evident in the 13 months of activity following its roll-out in April 2018, is that 11,000 clinicians have begun utilising the service and SafeScript has helped those clinicians identify 15,000 instances of a person visiting more than four health providers for monitored medicines within the specified time period. SafeScript also helped to identify 13,000 people who were prescribed doses that could be excessive, or in combinations that could increase risks. There is a clear advantage for a pharmacist to have access to this information when making a decision about the appropriateness or safety of supplying a medicine at a specific point in time, especially from the perspective of assisting a person to access different services that may be relevant to their circumstances.
RegistrationThe process of registering for SafeScript is relatively simple, and requires two specific activities to be completed:
Every pharmacist registers through the SafeScript portal at www.safescript.vic.gov.au. This will require your AHPRA registration, date of birth, and contact details for the pharmacy at which you will access SafeScript.
- Individual registration:
Visit vic.health1 for instructions on downloading SafeScript software for each terminal used within the pharmacy. You will also find instructions for ‘manual’ access via the portal for systems that do not yet have integrated software solutions.
- Enabling software:
Implementation tipsImplementing SafeScript in isolation from your colleagues is less than ideal. A discussion in the workplace about the ease of implementation and wealth of clinical information SafeScript provides can help to ensure that all staff within the pharmacy are aware of the role of SafeScript, correct processes for accessing a person’s record, and how to proceed in the instance where a pharmacist identifies a request to dispense what they consider unsafe. Importantly, each pharmacist needs to register individually for SafeScript – accessing a person’s medical information under another heath professional’s credentials is not permitted. Pharmacists should familiarise themselves with referral pathways for allied health, specialist pain treatment options, specialist substance use disorder options, and the use of motivational counselling to overcome dangerous health choices.
Other statesThe Federal Government has committed to a national Real Time Prescription Monitoring (RTPM) service, interoperability between state and territory systems. Most states and territories are now actively working towards implementing RTPM systems in their jurisdictions. The impact of SafeScript as a clinical tool on medicine safety is clear. RTPM cannot come soon enough to the rest of Australia’s prescribers and pharmacists.
|Lodge your own question at firstname.lastname@example.org|
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7431 [post_author] => 10 [post_date] => 2019-08-28 01:12:30 [post_date_gmt] => 2019-08-27 15:12:30 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] Conducting research can be a daunting prospect. But by choosing a mentor and working intelligently, pharmacists can research and have their work published. A study published earlier this year in the Journal of Pharmacy Practice and Research found that pharmacists have a keen interest in conducting research.1 Yet these same pharmacists had comparatively low levels of research confidence and experience. The lack of confidence is understandable, as research and publication can be a formidable, lengthy undertaking. Thankfully, no one expects early career pharmacists (ECPs) to launch straight into a randomised control trial by themselves. But while practising pharmacists may not always seem themselves as researchers, leading academics say the opposite is true. ‘Pharmacists working in clinical practice are in an ideal position to identify opportunities to change health care for the better,’ says Professor Simon Bell MPS, Director at Monash University’s Centre for Medicine Use and Safety. ‘Doing research is a way to explore those opportunities for change, to generate evidence that’s necessary to bring about change in clinical practice or health policy.’ So picture an ECP at work, wanting to get involved in research, with the distant goal of publishing work – where do they start? ‘Simple audit processes of the way you do things in your clinical practice is important research, and that can lead on to publications,’ says John Coutsouvelis, Senior Oncology and Haematology Pharmacist at Alfred Health, and a Senior Lecturer at Monash University. ‘It could be clinical, it could be a process. Start with audits and drug usage evaluations in hospitals. If you’re in community pharmacy, start with an audit of customer satisfaction with services. It’s all simple research, but starts you thinking about how to set up a study and what you’re measuring.’ Meredith Wiseman, a Senior Lecturer at Monash University, also encourages practising pharmacists to start with their own scope of practice. ‘Question what you see around you, and if you have a question, raise it with the people you work with – that’s often the start of more discussion around potential research projects,’ she says. Discussing practice with colleagues and seniors is not only useful in mapping out a research question, but often yields potential opportunities for participating or collaborating with other projects and researchers. ‘Researchers are passionate about what they do and are happy to discuss research opportunities with any pharmacist,’ says Professor Bell. ‘Make an appointment with academic staff at your university, or if you’re working in a hospital, approach the director of pharmacy for advice. Universities and hospitals often have ongoing research projects that pharmacists can get involved in. This is a great way to gain experience.’ Mr Coutsouvelis also recommends that those who are looking to conduct research attend conferences in their field. ‘They’re a great way to start understanding what you need to put in an abstract and the things that reviewers look for.’ When it comes to developing a research question, Ms Wiseman encourages pharmacists to read academic literature. ‘It provides a good background. Read, read, read, talk with collaborators, get involved, and put yourself out there,’ she says. ‘Hospitals and other institutions often run journal clubs that can be a great resource for keeping abreast of current research.’ Reading naturally leads into the next step of research – a literature review. ‘It’s important to understand what’s already been published,’ says Professor Bell. ‘Often people come up with good ideas, but when they look further into the research literature they find several other studies have covered the area. It’s important to think about what your research will add.’
Determining methodsAfter identifying a research topic, pharmacists need to determine the research methodology for their study. For those new to research, this can be the most daunting stage of a study. ‘People often want to do complex research, but it’s more important to pick a methodology that is suitable to your question and that may mean a simpler methodology,’ says Mr Coutsouvelis. Professor Bell says one common reason studies are rejected for publication is due to concerns over methodological quality. ‘I would encourage people to have a discussion with their research mentor about the most appropriate methods before they start doing their research,’ he says. ‘That way, the time and resources they invest will produce the best returns on investment and a high-quality piece of evidence at the end.’ Looking at past research can also help. ‘Go back to the literature and see how people have studied a similar topic in a different area, or a similar thing with a different drug, and try and map your methodology out that way,’ says Mr Coutsouvelis.
Finding that journalWhen it comes to publishing research, finding the right journal can be a challenge. ‘There are many different scientific journals out there, with different readerships,’ says Professor Bell. ‘It’s important to keep your readership in mind when writing your article and selecting a target journal. Work is often rejected because it’s outside the scope of the journal, so you need to target your work to the right readership.’ A good place to start, says Ms Wiseman, are the professional journals. ‘Australian Pharmacist, the Journal of Pharmacy Practice and Research – they’re obviously going to be good links.’ She also advises close collaboration with experienced researchers. ‘Work with them to identify the best journal, and then read those journals yourself to ensure they fit your theme.’ When it comes to identifying and submitting to journals, Professor Bell says an experienced research mentor can save time, avoid needless rejections, and help optimise the impact of your work. ‘Regardless of where you choose to publish your research, it’s important to have a good research mentor who can guide you through that process. Publishing doesn’t have to be a daunting experience. ‘It’s fantastic when a student or pharmacist comes to us with an idea for research – it’s the kind of innovation and enthusiasm we need. But it’s important to take the time to work with a research mentor to help ensure that your proposed work is novel and the methods are rigorous before getting started.’
Dealing with rejectionWhen it comes to the final step of publishing their work, should new researchers expect to be knocked back by journals? ‘Even experienced researchers have their papers rejected,’ says Professor Bell. ‘The good journals only accept a small percentage of the articles they receive. If you do receive a rejection, that doesn’t mean that the work wouldn’t be suitable to be published in another journal. It can be easy to feel disappointed when a manuscript is rejected, but people shouldn’t lose heart if that happens.’ Having a research mentor is important as they can help identify more suitable journals to submit work to, and it requires patience. ‘ECPs sometimes expect something straight away, which is not a criticism. But to really get a good paper published can sometimes take a year,’ says Mr Coutsouvelis. Reaching publication is a consultative process between researchers, publishers and reviewers. ‘Any article will go through several rounds of peer review and editing before it’s submitted for publication, so don’t get disheartened,’ he says. References
- Waddell J. Research confidence, interest and experience of an Australian hospital pharmacy population. Journal of Pharmacy Practice and Research. May 2019. doi.org/10.1002/jppr.1480. At: https://onlinelibrary.wiley.com/doi/abs/10.1002/jppr.1480
|Submit your research to AP at email@example.com|
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7509 [post_author] => 196 [post_date] => 2019-08-12 13:17:30 [post_date_gmt] => 2019-08-12 03:17:30 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] It’s no longer plain sailing in Australian community pharmacy. Bruce Annabel helps navigate in this, the fourth instalment of our Future Health series. Most have heard the saying, ‘You cannot direct the wind, but you can adjust the sails.’ The nautical analogy is helpful. Pharmacy has sailed along propelled by the winds of regulation; the exclusive distribution of PBS pharmaceuticals and scheduled medicines have generated patient visits and profit. In return, consumers have received a reliable, accessible medicine distribution network. But in an era of tectonic change, is that sufficient to maintain pharmacy’s financial returns and relevance in the health spectrum? The winds of change are blowing hard on the traditional business model, requiring owners, peak bodies, industry and the profession to assess where community pharmacy now stands. Initiatives are needed to harness these forces, beginning with the forthcoming Seventh Community Pharmacy Agreement (7CPA).
Winds of change
1. Market and technologyThe key to community pharmacy success has been location, maximising script throughput, and operating efficiently as a business. However, fundamental change in the competitive and technological landscape has resulted in flat script volumes and falling patient visits pressuring profitability and viability. One of the biggest concerns is falling patient visits, down 3.8% during the last five years including 1.9% last year,1 reflecting the reduced market relevance of the traditional business model. Therefore, historical success factors have become ‘hygiene’, and it’s getting worse because few are responding appropriately to the changes.
2. Blown off courseUnfortunately, price discounting is the result, financed by cutting wages and pressuring suppliers for deals that no longer exist. Something has to change – net profit is down 22% compared with five years ago, while return on investment has fallen to 14% compared with 25% just 10 years ago.1 Pharmacists clinging to the script-processing role means ‘pharmacist professional service’ is inconsistently delivered to patients, who are left to interact with pleasant assistants. That is referred to as ‘service’, which is now a ‘hygiene’ factor too. But even though it has been blown off course, the old model is chugging along, made possible by dispensing profitability sufficient to hold the bottom line together … for the time being.
3. CommoditisationBecause of price discounting and wage cuts, pharmacists are working even harder processing scripts with less time for advice and professional services. The result is that patients and the community have been trained to value pharmacies based on price instead of health benefits i.e. an industry focused on ‘selling to customers’ instead of ‘helping patients’. The majority of new medicines being listed on the PBS are highly specialised, usually high cost, and mostly delivered to patients in hospital or specialist practices. Pharmacy has been left primarily dispensing cheap off -patent pharmaceuticals with an average cost of $25.1 Many of these medicines have become commoditised by competing for market share through price discounting in a flat market.
4. Federal governmentPBS script volume fell by 2 million between 2013/14 and 2017/18 and net outlays have been flat in nominal terms for 10 years. That policy will continue, evidenced by the April 2019 budget forecasting expenditure of $9.7 billion in 2022/23 compared with the 2018/19 estimate of $9.6 billion. So the government expects costly new medicines to be paid for by the industry, manufacturers, distributors and perhaps even pharmacy. Perhaps that was the motivation behind the proposed extended 60-day script supply for 143 drugs. The proposal could resurface!
5. Cyclonic windsWinds of change may turn cyclonic as the Fourth Industrial Revolution gathers pace. It has been written: ‘During the next three years, the Fourth Industrial Revolution will really take hold as technologies in the physical, digital and biological spheres begin to come together under the impetus of ‘the internet of things’, artificial intelligence, robotics and additive manufacturing.’2 Immunotherapy, gene and cell therapy, along with technological convergence, will fundamentally reshape the industry.
Adjusting the sailsThere is much support for pharmacist-only ownership, although it should be capitalised on by utilising their skills and trust with patients. Innovation in the quality of the patient offer is the key to a non-price competitive value equation aimed at holding existing patients, attracting new ones and giving them great reasons to return. Some pharmacies have done this by offering patients innovative services. This includes minor ailments, mental health, medication management and condition management in addition to script supply and advice. These innovative pharmacies outperform the industry standard in most measures, including earning professional services income over $100,000 pa, some $300,000 pa, compared with the average of a touch above $30,000.1 Virtually every pharmacy is capable of operating that model but they lack the incentive and/or implementation assistance. The innovators model should be adopted as the industry framework. The key elements are:
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 5170 [post_author] => 82 [post_date] => 2019-05-16 09:13:50 [post_date_gmt] => 2019-05-15 23:13:50 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] Faye McMillan is a pioneer, paving the way for other Aboriginal and Torres Strait Islander people who want to work in the pharmacy profession. When she’s not busy winning awards, she works as a community pharmacist, university lecturer and is a founding member of Indigenous Allied Health Australia.
Why did you decide to become a pharmacist?Over 20 years ago, I was working as a pharmacy assistant in my hometown of Trangie (NSW) when I thought to myself, ‘I actually want to be the pharmacist.’ The pharmacist I was working with at the time was extremely supportive and encouraged me to apply to study. I ended up being part of the inaugural cohort of students when Charles Sturt University introduced their pharmacy program in Wagga Wagga, NSW in 1997.
What’s the main focus of your practice?I’m a community pharmacist, and I also teach in the area of Indigenous health, mental health and pharmacy at CSU. But the main focus of my work is patient-centred care, and ensuring that I’m working with people, so that they feel engaged. That’s what really drew me to pharmacy in the first place – an opportunity to have a relationship and help people as they navigate their health journey.
You’re passionate about recruiting Indigenous Australians into healthcare. What work do you do in this area?As a founding member of Indigenous Allied Health Australia (IAHA), we strive to recognise Aboriginal and Torres Strait Islander people in the allied health workforce. I sat on the board from its inception in 2009 until 2017 and I was also the chair from 2010–2016. We started with just seven members, now we have 1,500. IAHA is seen as one of the key bodies representing Aboriginal and Torres Strait Islander people to government and was involved in the development and implementation of the National Aboriginal and Torres Strait Islander Health Plan. We also work with universities to ensure that when Aboriginal and Torres Strait Islander students undertake allied health courses, they are being provided with support, mentors and networking opportunities. But at IAHA, it’s not just about how we recruit people, it’s how we retain them. We work to ensure they feel engaged, not just in their profession but as a part of their community in the form of a trained healthcare professional.
You were Australia’s first registered Indigenous pharmacist and won the 2019 NSW Aboriginal Woman of the Year Award. How do you feel about being a role model?It didn’t sit comfortably at first, but I think I’ve settled into it and recognised that people do need role models. When I was starting out I looked around for role models, and I appreciated the journeys of the people who I looked up to. If I’m that to someone else, then that’s a wonderful thing. Sometimes you’re able to use the platform of being an award recipient to give a nuanced opinion or view, and we need people to take up those positions.
You’re also a member of PSA’s National Aboriginal Community Controlled Health Organisation Leadership Group. Why is pharmacist intervention in Indigenous health so important?Pharmacists play an integral role in the lives of so many people, whether clinically, in the community, or in hospitals – there are so many touch points where pharmacists can be included to provide insight into the health of Aboriginal and Torres Strait Islander people. The knowledge and skills that pharmacists have through their education, their life experiences and by being a consistent presence in the community means that they are able to provide a point of reference for other health professionals. The Leadership Group is making significant contributions by ensuring people have access to a highly skilled and trained workforce, as well as providing education around the medicines that are needed in these communities, while ensuring they are accessible and affordable.
What’s the next big project that you’re working on?I’m putting the final touches on a mental health app that I’ve been developing over the past 18 months. I wanted to create something that would provide meaningful support to people – not in place of trained mental health professionals, of course. The app is an extension of an existing self-awareness app that keeps you connected with people you’ve identified in your contact list as your ‘caring community’. It assesses where people are sitting on the scale of mental wellness, followed by contact from someone who will reach out and have a conversation with you. It’s all about having real conversations – listening out for warning signs such as changes in the timbre of the voice, and pauses, things that are easily masked in social media use. Get more news at www.australianpharmacist.com.au [/vc_column_text][/vc_column][vc_column width="1/3"][/vc_column][/vc_row] [post_title] => Pushing boundaries: the pioneer pharmacist [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => pushing-boundaries-the-pioneer-pharmacist [to_ping] => [pinged] => [post_modified] => 2019-05-16 11:27:59 [post_modified_gmt] => 2019-05-16 01:27:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=5170 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Pushing boundaries: the pioneer pharmacist [title] => Pushing boundaries: the pioneer pharmacist [href] => https://www.australianpharmacist.com.au/pushing-boundaries-the-pioneer-pharmacist/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 5171 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 4455 [post_author] => 20 [post_date] => 2019-03-07 21:35:04 [post_date_gmt] => 2019-03-07 11:35:04 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] A range of apps enable pharmacists and patients to see and/or manage their medical information. As the benefits of My Health Record (MHR) become more widely known, its uptake and usage can be expected to grow. As pharmacists, we are well positioned to take a leadership role and guide patients on this topic, given our status as the most digitally enabled of all health professionals. It is important for patients who wish to play an active role in their healthcare, or carers of vulnerable patient groups (e.g. children, disabled, elderly, mentally impaired), to understand what information is available to them and how they can access and control access to clinical documents (shared health summary, discharge summary, pathology, diagnostic imaging), prescriptions (prescriptions issued and dispense uploads), consumer documents (patient health summaries, patient notes) and Medicare documents (e.g. immunisation register, organ donor status, Medicare benefits).
How do patients access their MHR?There are two ways for patients to access their My Health Record. 1. WEB PORTAL (myrecord.ehealth.gov.au) This site:
|Using a great smartphone app with your patients? Share your insights with your colleagues. Email firstname.lastname@example.org and tell us about your experience and the results you’ve seen.|
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7520 [post_author] => 82 [post_date] => 2019-08-15 13:49:41 [post_date_gmt] => 2019-08-15 03:49:41 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] Deirdre Criddle FPS is a complex care coordinator pharmacist at Sir Charles Gairdner Hospital in WA, and also a senior pharmacist steering professional services and development. It keeps her busy – and inspired.
Can you tell us what your complex care role entails?It’s quite new. In 2012, an inter-disciplinary team of advanced practitioners – nurses, social workers, occupational therapists, physiotherapists – were charged with improving health system navigation for complex patients. They asked Bruce Williamson, an experienced clinical pharmacist, if he could upskill them. Bruce tried to draft a program, but basically said, ‘You don’t need upskilling – you need a pharmacist embedded in your team.’ So he started this journey and I have been fortunate enough to follow in his footsteps since 2014. It’s now three days a week in an inter-disciplinary team. I do a lot of intensive work in medication management for patients who are medically complex. It’s a fantastic position, I love it, and it’s growing. I think there’s a huge opportunity for progression in that area – hospitals are facing such difficulty with patients becoming more complex, and pharmacists are an integral part of the solution.
What got you started in hospital settings?I’ve had a varied journey. I started as a hospital pharmacist, then was with NPS MedicineWise for 14 years as an educational visiting pharmacist, which was invaluable. I branched into being an independent accredited pharmacist doing medicines reviews, and I hoped to make a career of that. But the cap came along in 2014, and that killed it. That’s when I came back into hospital pharmacy at Sir Charles Gairdner. And I heard Bruce talking at a clinical pharmacy meeting about his role, and I just thought, ‘Oh, I so want that job.’ Everything that I had done to that point was consolidated in that role. That’s what brought me back. But I’m a bit of a jack-of-all-trades. I see the value in every aspect of our profession. It’s not like this role is better than that role. I would never dream of doing anything else.
You’re also a Director of the Society of Australian Hospital Pharmacists (SHPA). What are today’s biggest challenges in hospital settings?It’s a very challenging environment. The need to prioritise is paramount, and that’s a difficult thing. In my role as a care coordinator pharmacist you are dealing with stressed patients, and also stressed staff. They’re working with insufficient resources, staffing levels are not what they should be, patient complexity is increasing ... basically, they’re working in a very stretched system. If you’re spending all your time with your nose to the grindstone, there’s no opportunity to do the reflection to ask, ‘How can I do my job better?’ That can only come if you’re given room to breathe. Trying to get those in power to understand the value pharmacists bring to complex systems, especially to reduce medicine-related harm across the patient journey, that’s where we need to go.
How would you like to see pharmacists’ roles in complex care develop?For my first two years in this role, people would say, ‘What’s a pharmacist doing in a complex care coordination team?’ My dream now is that everyone will say, ‘Where’s the pharmacist?’ There are people like me all across Australia, and that is so exciting. Sometimes you think you’re alone, but I can guarantee you you’re not. If we have mechanisms to network, and to improve the collaboration and sharing across our profession, especially in these emerging areas of practice, it can only be a good thing.
A DAY IN THE LIFE of Deirdre Criddle, hospital pharmacist8.00am: The day begins Connect with the cardiology pharmacist, who updates the team on new guidelines. Take a phone call from a clinical pharmacist concerned about a patient. 9.00am: Stopovers Visit a ward with a family, telephone interpreter in tow. Consent gained for a visit with an on-site interpreter in two days. 10.00am: Drive by Home visit with a patient who is confused by medicine changes. I make a phone call to his GP and General Medicine Consultant to discuss. Arrange a visit with patient at GP clinic the following day to trial a dose administration aid. 12.30pm: Meetings Meet with Head of Pharmacy Gillian Babe and Clinical Pharmacist David Lui to discuss the results of the Medicines Management Mapping Project about facilitating early post discharge using community and hospital pharmacists. 2.00pm: More meetings Catch up with the clinical nurse leads for the Cognitive Impairment Committee to discuss content development for an education package dedicated to antipsychotics prescribed in the hospital setting. 3.00pm: And another ... Multidisciplinary team meeting with CoNeCT social worker, pain consultant and addiction specialist to discuss concerns for a patient. 4.00pm: Check in What’s new in the email inbox? Check new referrals, and plan visits for the coming week. Phone patients scheduled for an outreach visit. 9.00pm: Moonlighting Teleconference with the International Pharmaceutical Federation (FIP) Working Group, based in the Netherlands. Final review of The pharmacist’s role in beating noncommunicable diseases. High fives all round as we agree to final edits and submit to the FIP Council for approval.
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7523 [post_author] => 82 [post_date] => 2019-08-05 13:56:33 [post_date_gmt] => 2019-08-05 03:56:33 [post_content] => [vc_row][vc_column width="2/3"][vc_column_text] Luke Vrankovich MPS, a former locum and one half of the Roaming Pharmacist duo, gained an online following living life on the road. So how is pharmacy ownership working out?
Can you describe the ethos of The Roaming Pharmacist?It was started by Liam Murphy a few years ago. It was a way, using social media, to show how you can be a locum and travel at the same time. It was also a way to educate the public on some key ideas that are important to Liam, such as harm minimisation through pill testing at festivals. I came on board and began locuming around the country, incorporating my passion into my work, which is mental health. Ethos? I’d say sharing our adventures and educating along the way.
What are some of the most interesting places that your work as a locum has taken you?I’ve been all over. I took a road trip down the coast of New South Wales (NSW) and Victoria – I ended up rock climbing in Arapiles. One of my favourite places was Broome in Western Australia (WA) – really interesting work and a good group of people. Another favourite was Merimbula in NSW – a great sense of community. The pharmacy staff made me feel very welcome.
How did you adapt to the different legislation when moving between states?It required a bit of brain power to look out for the differences, mainly with the scripts on file and Schedule 8 medicines. The easiest way to adapt was to do some research beforehand so I would have a rough idea of how things worked, but I also leaned on the other pharmacists around me. I didn’t necessarily need to know everything in intricate detail before I got there, it was more about knowing what questions I needed to ask when certain situations arose.
You now own a pharmacy in Townsville. Why did you make the switch?Just over a year ago I was on a six-month trip around Australia, but I only made it to Carnarvon in WA when I got a call from my former boss in Coffs Harbour about an opportunity to run a pharmacy in Townsville. I thought it might be a while before another opportunity presented itself, so I took the plunge. It’s a very different lifestyle to working as a locum and comes with its own set of challenges, but I’ve always wanted to own my own pharmacy so I could prepare myself and my family for the future.
You’re a former mental health first aid facilitator. Do you use these skills a lot in your pharmacy practice?I use them every day. What’s great about mental health first aid is that it teaches you how to pick up on signs and approach conversations with more confidence. In a busy pharmacy, it’s easy to get caught in the cycle of receiving a repeat prescription for escitalopram, for example, and just dispense it. But the training empowers you to want to have that conversation with every person that comes through who takes an antidepressant – whether it’s new or continued. It’s important to ask how it’s been working for them, and if they’ve been on it for a while, if they are happy with the results. Sometimes this leads to deeper conversations around efficacy and adherence, which almost always turns to treatment recommendations or referrals.
Do you think other pharmacists would benefit from training in mental health first aid?A lot of pharmacists lack confidence to approach the conversations around mental health, particularly if a person has suicidal thoughts and they are voicing that within the pharmacy. It’s definitely not an easy situation to be in and it takes its toll. Nothing will ever fully prepare you, but the confidence you develop through training, along with the knowledge about the right referral points, particularly in acute situations, certainly helps.
You’re a former ECP of the Year, in 2017. Where do you see pharmacy practice going in the future?I see pharmacists specialising in one way or another. PSA is doing great work with pharmacists in general practice and pharmacist vaccination services have also been expanding. A lot of pharmacies try and be everything to everyone, but it’s not sustainable for community pharmacies to be across all areas of health care. I think the profession will branch out further into specialties and that the pathways will become more official.[/vc_column_text][/vc_column][vc_column width="1/3"][/vc_column][/vc_row] [post_title] => From locum to pharmacy owner [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => locum-pharmacy-owner-roaming-pharmacist [to_ping] => [pinged] => [post_modified] => 2019-08-15 17:37:19 [post_modified_gmt] => 2019-08-15 07:37:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=7523 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => From locum to pharmacy owner [title] => From locum to pharmacy owner [href] => https://www.australianpharmacist.com.au/locum-pharmacy-owner-roaming-pharmacist/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 7525 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7211 [post_author] => 82 [post_date] => 2019-07-29 11:14:27 [post_date_gmt] => 2019-07-29 01:14:27 [post_content] => The social highlight of the annual PSA conference is the Gala Dinner, and this year certainly did not disappoint. [gallery type="flexslider" size="large" ids="7224,7225,7226,7227,7229,7228,7230,7232,7231"] [post_title] => Pharmacists shine at the PSA19 Gala Dinner [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => pharmacists-shine-psa19-gala-dinner [to_ping] => [pinged] => [post_modified] => 2019-07-30 10:31:21 [post_modified_gmt] => 2019-07-30 00:31:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=7211 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Pharmacists shine at the PSA19 Gala Dinner [title] => Pharmacists shine at the PSA19 Gala Dinner [href] => https://www.australianpharmacist.com.au/pharmacists-shine-psa19-gala-dinner/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 7226 )
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7197 [post_author] => 82 [post_date] => 2019-07-28 10:00:16 [post_date_gmt] => 2019-07-28 00:00:16 [post_content] => University of Western Australia student Alice Hashiguchi was awarded the 2019 PSA Mylan Pharmacy Student of the Year (PSOTY) Award last night. Ms Hashiguchi was selected from a group of six finalists for demonstrating exceptional skills in a practical setting. PSA National President Dr Chris Freeman congratulated Ms Hashiguchi on her exceptional achievement. ‘The PSOTY Award gives outstanding pharmacy students the chance to showcase their counselling skills to their peers and the wider profession,’ Dr Freeman said. Dr Freeman also acknowledged the high calibre of this years finalists: ‘We saw many rising stars of pharmacy apply their clinical knowledge and communication skills in this year’s competition.’ This year's six finalists included:
td_module_mega_menu Object ( [authorType] => [post] => WP_Post Object ( [ID] => 7149 [post_author] => 82 [post_date] => 2019-07-27 10:45:53 [post_date_gmt] => 2019-07-27 00:45:53 [post_content] => In case you missed it, here's some of the action from the first day of PSA19 – from the Welcome Reception, Early Career Pharmacists Party and Fellows Dinner. [gallery type="flexslider" size="large" ids="7154,7155,7158,7151,7153,7152,7156,7157"] [post_title] => Highlights from PSA19, day one [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => highlights-from-psa19-day-one [to_ping] => [pinged] => [post_modified] => 2019-07-30 10:32:34 [post_modified_gmt] => 2019-07-30 00:32:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://www.australianpharmacist.com.au/?p=7149 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [title_attribute] => Highlights from PSA19, day one [title] => Highlights from PSA19, day one [href] => https://www.australianpharmacist.com.au/highlights-from-psa19-day-one/ [module_atts:td_module:private] => Array ( ) [td_review:protected] => Array ( ) [is_review:protected] => [post_thumb_id:protected] => 7152 )
Get your weekly dose of the news and research you need to help advance your practice.
Australian Pharmacist is the official journal for Pharmaceutical Society of Australia Ltd.